Sex Hormone-Binding Globulins and Testosterone Levels as a Risk Marker for Type 2 Diabetes Mellitus among Postmenopausal Women.
Insulin resistance
menopause
sex hormone-binding globulins
testosterone
type 2 diabetes mellitus
Journal
Journal of mid-life health
ISSN: 0976-7800
Titre abrégé: J Midlife Health
Pays: India
ID NLM: 101552746
Informations de publication
Date de publication:
Historique:
received:
06
07
2020
revised:
20
04
2021
accepted:
23
05
2021
entrez:
16
9
2021
pubmed:
17
9
2021
medline:
17
9
2021
Statut:
ppublish
Résumé
Endogenous sex hormones and sex hormone-binding globulins (SHBG) determine the risk of occurrence of Type 2 diabetes mellitus (T2DM) in postmenopausal (PM) women. To investigate the association between sex hormones (estradiol and testosterone) and SHBG with plasma glucose, fasting insulin levels, HbA1c, and homeostasis model assessment insulin resistance (HOMA-IR) and also to investigate independent role of sex hormones in the occurrence of T2DM among PM. Cross-sectional case-control study. The present study was conducted in Endocrinology department Guwahati, Medical College, Assam, India. The participants included cases - PM women with T2DM ( Pearson correlation between sex hormone level and SHBG with plasma glucose, HbA1c, fasting insulin, hs-CRP, and HOMA-IR was seen. Multivariance logistic analysis was done to find the independent association between sex hormones/SHBG and the occurrence of T2 DM. P < 0.05 was considered statistically significant. Among the cases, a significant positive correlation was found between total testosterone/free testosterone index with waist circumference, FPG PPPG, HbA1c, fasting insulin, and HOMA-IR, and a significant negative correlation was found between SHBG and FPG, PPPG, HbA1c, fasting insulin, and HOMA-IR ( SHBG and testosterone levels in PM can be a risk marker for the development of T2DM.
Sections du résumé
BACKGROUND
BACKGROUND
Endogenous sex hormones and sex hormone-binding globulins (SHBG) determine the risk of occurrence of Type 2 diabetes mellitus (T2DM) in postmenopausal (PM) women.
AIMS
OBJECTIVE
To investigate the association between sex hormones (estradiol and testosterone) and SHBG with plasma glucose, fasting insulin levels, HbA1c, and homeostasis model assessment insulin resistance (HOMA-IR) and also to investigate independent role of sex hormones in the occurrence of T2DM among PM.
SETTINGS AND DESIGN
METHODS
Cross-sectional case-control study.
SUBJECTS AND METHODS
METHODS
The present study was conducted in Endocrinology department Guwahati, Medical College, Assam, India. The participants included cases - PM women with T2DM (
STATISTICAL ANALYSIS
METHODS
Pearson correlation between sex hormone level and SHBG with plasma glucose, HbA1c, fasting insulin, hs-CRP, and HOMA-IR was seen. Multivariance logistic analysis was done to find the independent association between sex hormones/SHBG and the occurrence of T2 DM. P < 0.05 was considered statistically significant.
RESULTS
RESULTS
Among the cases, a significant positive correlation was found between total testosterone/free testosterone index with waist circumference, FPG PPPG, HbA1c, fasting insulin, and HOMA-IR, and a significant negative correlation was found between SHBG and FPG, PPPG, HbA1c, fasting insulin, and HOMA-IR (
CONCLUSION
CONCLUSIONS
SHBG and testosterone levels in PM can be a risk marker for the development of T2DM.
Identifiants
pubmed: 34526751
doi: 10.4103/jmh.JMH_142_20
pii: JMH-12-155
pmc: PMC8409708
doi:
Types de publication
Journal Article
Langues
eng
Pagination
155-160Informations de copyright
Copyright: © 2021 Journal of Mid-life Health.
Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
Pediatrics. 2007 Aug;120(2):340-5
pubmed: 17671060
Ann Intern Med. 2003 Jan 7;138(1):1-9
pubmed: 12513038
J Midlife Health. 2016 Oct-Dec;7(4):169-174
pubmed: 28096640
JAMA. 2006 Mar 15;295(11):1288-99
pubmed: 16537739
Hypertension. 1996 Oct;28(4):576-82
pubmed: 8843881
Menopause. 2011 Apr;18(4):376-84
pubmed: 21107300
Circulation. 2005 Apr 19;111(15):1883-90
pubmed: 15837940
Eur J Clin Invest. 2013 Feb;43(2):159-67
pubmed: 23278315
Am J Physiol Endocrinol Metab. 2008 Jan;294(1):E15-26
pubmed: 17957034
Breast Cancer Res Treat. 2009 May;115(1):171-9
pubmed: 18509757
Int J Endocrinol Metab. 2013 Spring;11(2):65-70
pubmed: 23825975
J Clin Endocrinol Metab. 2009 Nov;94(11):4127-35
pubmed: 19789205
J Midlife Health. 2012 Jan;3(1):24-30
pubmed: 22923976
JAMA. 2002 Oct 9;288(14):1723-7
pubmed: 12365955
Eur J Endocrinol. 2004 Feb;150(2):161-71
pubmed: 14763914
Lancet. 2005 Sep 24-30;366(9491):1059-62
pubmed: 16182882
Arch Intern Med. 2002 Sep 9;162(16):1867-72
pubmed: 12196085
Am J Epidemiol. 2002 Nov 1;156(9):832-41
pubmed: 12397001
J Am Coll Cardiol. 2018 Jun 5;71(22):2555-2566
pubmed: 29852978
N Engl J Med. 2009 Sep 17;361(12):1152-63
pubmed: 19657112
Atherosclerosis. 2007 Nov;195(1):e191-6
pubmed: 17482196
Am J Hypertens. 2003 Jul;16(7):537-43
pubmed: 12850386
Diabetologia. 2007 Oct;50(10):2076-84
pubmed: 17701157
Diabetes Care. 2002 Jan;25(1):55-60
pubmed: 11772901
Int J Obes Relat Metab Disord. 2001 Jan;25(1):98-105
pubmed: 11244464
JAMA. 2001 Jul 18;286(3):327-34
pubmed: 11466099